| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Surgical Procedures | 54 | 2026 | 270 | 17.270 |
Why?
|
| Acute Kidney Injury | 18 | 2025 | 142 | 7.380 |
Why?
|
| Scabies | 24 | 2025 | 27 | 6.830 |
Why?
|
| Rheumatic Heart Disease | 18 | 2024 | 22 | 5.530 |
Why?
|
| Perioperative Care | 15 | 2026 | 86 | 3.190 |
Why?
|
| Thoracic Surgery | 9 | 2024 | 76 | 2.700 |
Why?
|
| Postoperative Complications | 22 | 2026 | 1301 | 2.590 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 210 | 2.320 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 223 | 2.300 |
Why?
|
| Anemia | 5 | 2024 | 128 | 2.230 |
Why?
|
| Humans | 136 | 2026 | 64272 | 1.980 |
Why?
|
| Coronary Artery Bypass | 12 | 2024 | 297 | 1.820 |
Why?
|
| Consensus | 14 | 2026 | 185 | 1.810 |
Why?
|
| Surgeons | 6 | 2024 | 182 | 1.790 |
Why?
|
| Practice Guidelines as Topic | 5 | 2024 | 726 | 1.670 |
Why?
|
| Impetigo | 8 | 2023 | 11 | 1.600 |
Why?
|
| Betacoronavirus | 6 | 2020 | 183 | 1.560 |
Why?
|
| Ivermectin | 12 | 2025 | 25 | 1.530 |
Why?
|
| Pandemics | 10 | 2023 | 676 | 1.490 |
Why?
|
| Heart-Assist Devices | 6 | 2026 | 149 | 1.440 |
Why?
|
| Penicillin G Benzathine | 5 | 2024 | 6 | 1.430 |
Why?
|
| Operating Rooms | 3 | 2020 | 57 | 1.390 |
Why?
|
| Neglected Diseases | 8 | 2022 | 11 | 1.270 |
Why?
|
| Heart Valve Prosthesis | 2 | 2023 | 114 | 1.240 |
Why?
|
| Antibiotic Prophylaxis | 4 | 2024 | 55 | 1.240 |
Why?
|
| Mass Drug Administration | 10 | 2025 | 13 | 1.230 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2025 | 63 | 1.230 |
Why?
|
| Medicare | 4 | 2022 | 611 | 1.170 |
Why?
|
| Secondary Prevention | 4 | 2024 | 164 | 1.160 |
Why?
|
| Antiparasitic Agents | 3 | 2025 | 10 | 1.120 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 437 | 1.090 |
Why?
|
| Biomarkers | 7 | 2022 | 1431 | 1.070 |
Why?
|
| Heart Diseases | 3 | 2020 | 220 | 1.030 |
Why?
|
| Rheumatic Fever | 2 | 2024 | 5 | 1.010 |
Why?
|
| Patient Care Team | 3 | 2020 | 340 | 0.990 |
Why?
|
| Child | 29 | 2025 | 4582 | 0.970 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2025 | 147 | 0.960 |
Why?
|
| Health Expenditures | 2 | 2017 | 122 | 0.950 |
Why?
|
| Coronary Artery Disease | 3 | 2024 | 320 | 0.940 |
Why?
|
| Complement Inactivating Agents | 1 | 2025 | 14 | 0.920 |
Why?
|
| Echocardiography | 9 | 2024 | 509 | 0.870 |
Why?
|
| Fluid Therapy | 2 | 2022 | 46 | 0.870 |
Why?
|
| Societies, Medical | 8 | 2025 | 381 | 0.850 |
Why?
|
| Goals | 2 | 2022 | 92 | 0.850 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 2 | 2020 | 5 | 0.820 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2024 | 128 | 0.810 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 14 | 0.810 |
Why?
|
| Postoperative Care | 3 | 2020 | 124 | 0.800 |
Why?
|
| Mass Screening | 6 | 2023 | 694 | 0.790 |
Why?
|
| Chest Tubes | 1 | 2023 | 17 | 0.790 |
Why?
|
| Delirium | 2 | 2020 | 55 | 0.790 |
Why?
|
| Fiji | 10 | 2023 | 11 | 0.790 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 248 | 0.780 |
Why?
|
| Health Resources | 3 | 2020 | 94 | 0.780 |
Why?
|
| Schools | 3 | 2023 | 170 | 0.780 |
Why?
|
| Inservice Training | 3 | 2021 | 87 | 0.770 |
Why?
|
| Infection Control | 2 | 2020 | 105 | 0.750 |
Why?
|
| Anti-Bacterial Agents | 6 | 2024 | 800 | 0.740 |
Why?
|
| Clinical Competence | 5 | 2021 | 730 | 0.740 |
Why?
|
| Prevalence | 13 | 2025 | 1407 | 0.720 |
Why?
|
| Cross Infection | 2 | 2020 | 167 | 0.720 |
Why?
|
| Benchmarking | 2 | 2020 | 134 | 0.720 |
Why?
|
| Public Health Administration | 1 | 2021 | 22 | 0.710 |
Why?
|
| Early Diagnosis | 2 | 2024 | 99 | 0.700 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 134 | 0.680 |
Why?
|
| Child, Preschool | 17 | 2025 | 2018 | 0.680 |
Why?
|
| Risk Factors | 19 | 2025 | 5341 | 0.680 |
Why?
|
| Recovery Room | 1 | 2020 | 3 | 0.660 |
Why?
|
| Risk Assessment | 9 | 2026 | 2048 | 0.650 |
Why?
|
| Adolescent | 22 | 2025 | 6306 | 0.650 |
Why?
|
| Reimbursement Mechanisms | 2 | 2017 | 41 | 0.650 |
Why?
|
| Aortic Valve Stenosis | 1 | 2023 | 190 | 0.650 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 120 | 0.640 |
Why?
|
| Length of Stay | 7 | 2025 | 819 | 0.640 |
Why?
|
| Prospective Payment System | 2 | 2017 | 8 | 0.640 |
Why?
|
| Nursing Staff, Hospital | 2 | 2020 | 71 | 0.640 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2025 | 788 | 0.640 |
Why?
|
| Treatment Outcome | 15 | 2025 | 5695 | 0.630 |
Why?
|
| Pressure Ulcer | 1 | 2020 | 34 | 0.630 |
Why?
|
| Shock, Cardiogenic | 3 | 2025 | 104 | 0.630 |
Why?
|
| Transfusion Reaction | 1 | 2019 | 45 | 0.620 |
Why?
|
| Intraoperative Care | 2 | 2020 | 38 | 0.610 |
Why?
|
| Stroke | 4 | 2023 | 1196 | 0.610 |
Why?
|
| Triage | 5 | 2022 | 128 | 0.610 |
Why?
|
| Bioprosthesis | 2 | 2023 | 42 | 0.600 |
Why?
|
| Male | 42 | 2025 | 30321 | 0.600 |
Why?
|
| Heart Failure | 2 | 2024 | 926 | 0.600 |
Why?
|
| Nutritional Support | 1 | 2019 | 12 | 0.600 |
Why?
|
| Awareness | 2 | 2022 | 75 | 0.580 |
Why?
|
| Disease Management | 1 | 2020 | 237 | 0.580 |
Why?
|
| Melanesia | 8 | 2021 | 8 | 0.570 |
Why?
|
| Purchasing, Hospital | 1 | 2017 | 1 | 0.550 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2017 | 5 | 0.550 |
Why?
|
| Interdisciplinary Communication | 2 | 2020 | 107 | 0.550 |
Why?
|
| Quality Control | 1 | 2017 | 74 | 0.540 |
Why?
|
| Retrospective Studies | 10 | 2024 | 6741 | 0.530 |
Why?
|
| Analgesics, Opioid | 2 | 2022 | 531 | 0.530 |
Why?
|
| Students | 1 | 2019 | 222 | 0.530 |
Why?
|
| Children's Health Insurance Program | 1 | 2017 | 3 | 0.530 |
Why?
|
| Work Engagement | 1 | 2017 | 14 | 0.530 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 11 | 0.520 |
Why?
|
| Adolescent Health Services | 1 | 2017 | 19 | 0.520 |
Why?
|
| Value-Based Purchasing | 1 | 2017 | 8 | 0.520 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 260 | 0.520 |
Why?
|
| Hospital Costs | 1 | 2017 | 126 | 0.510 |
Why?
|
| Female | 34 | 2025 | 33382 | 0.510 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 48 | 0.500 |
Why?
|
| Ultrasonography | 2 | 2016 | 486 | 0.500 |
Why?
|
| Heart Valves | 1 | 2016 | 26 | 0.490 |
Why?
|
| Pulmonary Embolism | 1 | 2018 | 175 | 0.480 |
Why?
|
| Time Factors | 9 | 2024 | 3725 | 0.470 |
Why?
|
| Prospective Studies | 12 | 2024 | 3318 | 0.470 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 154 | 0.470 |
Why?
|
| Drug Monitoring | 1 | 2017 | 206 | 0.460 |
Why?
|
| Computer-Assisted Instruction | 1 | 2016 | 80 | 0.460 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2017 | 771 | 0.460 |
Why?
|
| Critical Care | 3 | 2020 | 402 | 0.460 |
Why?
|
| Disease Outbreaks | 3 | 2021 | 116 | 0.450 |
Why?
|
| Adult | 27 | 2026 | 17136 | 0.450 |
Why?
|
| Postoperative Period | 3 | 2021 | 137 | 0.450 |
Why?
|
| Leadership | 1 | 2017 | 208 | 0.450 |
Why?
|
| Nurses | 1 | 2016 | 109 | 0.440 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2023 | 95 | 0.440 |
Why?
|
| Blood Transfusion | 4 | 2024 | 162 | 0.440 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 513 | 0.440 |
Why?
|
| Patient Compliance | 1 | 2016 | 362 | 0.430 |
Why?
|
| Coronary Care Units | 1 | 2013 | 4 | 0.420 |
Why?
|
| Hospital Information Systems | 1 | 2013 | 11 | 0.420 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 62 | 0.410 |
Why?
|
| Recovery of Function | 4 | 2024 | 286 | 0.390 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2010 | 32 | 0.390 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2025 | 45 | 0.380 |
Why?
|
| Heart | 6 | 2022 | 287 | 0.370 |
Why?
|
| Sarcopenia | 2 | 2024 | 28 | 0.370 |
Why?
|
| Foramen Ovale, Patent | 1 | 2012 | 13 | 0.370 |
Why?
|
| Aged | 17 | 2025 | 14663 | 0.360 |
Why?
|
| Health Personnel | 1 | 2016 | 389 | 0.360 |
Why?
|
| Mammary Arteries | 2 | 2022 | 11 | 0.360 |
Why?
|
| Embolism | 1 | 2012 | 41 | 0.360 |
Why?
|
| Young Adult | 13 | 2025 | 4782 | 0.350 |
Why?
|
| Physicians | 1 | 2017 | 483 | 0.350 |
Why?
|
| Skin Diseases, Bacterial | 2 | 2021 | 9 | 0.350 |
Why?
|
| Surgical Wound Infection | 2 | 2024 | 122 | 0.340 |
Why?
|
| Endemic Diseases | 3 | 2020 | 24 | 0.340 |
Why?
|
| Azithromycin | 3 | 2020 | 32 | 0.330 |
Why?
|
| United States | 10 | 2023 | 7923 | 0.330 |
Why?
|
| Delphi Technique | 4 | 2025 | 102 | 0.330 |
Why?
|
| Soft Tissue Infections | 2 | 2021 | 49 | 0.330 |
Why?
|
| Saphenous Vein | 1 | 2010 | 52 | 0.320 |
Why?
|
| Middle Aged | 17 | 2025 | 17923 | 0.320 |
Why?
|
| Mitral Valve | 2 | 2023 | 127 | 0.320 |
Why?
|
| Endoscopy | 1 | 2010 | 112 | 0.310 |
Why?
|
| Hemodynamics | 3 | 2024 | 249 | 0.310 |
Why?
|
| Sensitivity and Specificity | 3 | 2024 | 1164 | 0.310 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 2481 | 0.310 |
Why?
|
| Insecticides | 3 | 2019 | 45 | 0.300 |
Why?
|
| Nitric Oxide | 4 | 1996 | 174 | 0.280 |
Why?
|
| Advisory Committees | 2 | 2020 | 113 | 0.280 |
Why?
|
| Program Development | 3 | 2020 | 207 | 0.280 |
Why?
|
| ROC Curve | 2 | 2020 | 288 | 0.270 |
Why?
|
| Heart Valve Diseases | 3 | 2023 | 95 | 0.270 |
Why?
|
| Global Health | 3 | 2019 | 183 | 0.270 |
Why?
|
| Multicenter Studies as Topic | 2 | 2025 | 151 | 0.270 |
Why?
|
| Intensive Care Units | 3 | 2020 | 414 | 0.270 |
Why?
|
| Blood Loss, Surgical | 2 | 2024 | 65 | 0.270 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2025 | 58 | 0.260 |
Why?
|
| Uganda | 4 | 2024 | 56 | 0.260 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 2000 | 29 | 0.260 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 2738 | 0.250 |
Why?
|
| Victoria | 2 | 2024 | 7 | 0.250 |
Why?
|
| Cardiac Output, Low | 1 | 2026 | 11 | 0.250 |
Why?
|
| Odds Ratio | 2 | 2019 | 759 | 0.240 |
Why?
|
| Heart Arrest, Induced | 2 | 1996 | 13 | 0.240 |
Why?
|
| Infant | 8 | 2025 | 1664 | 0.240 |
Why?
|
| Australia | 5 | 2024 | 126 | 0.220 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2024 | 13 | 0.220 |
Why?
|
| Disease Progression | 3 | 2024 | 1174 | 0.220 |
Why?
|
| Sternum | 2 | 2023 | 29 | 0.220 |
Why?
|
| Hypoxia | 2 | 1995 | 116 | 0.210 |
Why?
|
| Postoperative Hemorrhage | 1 | 2024 | 40 | 0.210 |
Why?
|
| Selenium | 1 | 2024 | 25 | 0.210 |
Why?
|
| Incidence | 5 | 2021 | 1386 | 0.210 |
Why?
|
| Malaria | 1 | 2025 | 153 | 0.210 |
Why?
|
| Radial Artery | 1 | 2004 | 54 | 0.200 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 153 | 0.200 |
Why?
|
| Standard of Care | 1 | 2023 | 27 | 0.200 |
Why?
|
| Administration, Topical | 2 | 2020 | 51 | 0.200 |
Why?
|
| Virulence | 2 | 2020 | 195 | 0.200 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2003 | 118 | 0.190 |
Why?
|
| Extracellular Matrix | 1 | 2023 | 139 | 0.190 |
Why?
|
| Attitude of Health Personnel | 3 | 2018 | 620 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2024 | 172 | 0.190 |
Why?
|
| World Health Organization | 2 | 2019 | 34 | 0.190 |
Why?
|
| Logistic Models | 4 | 2020 | 1270 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 162 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2023 | 207 | 0.190 |
Why?
|
| Stroke Volume | 1 | 2024 | 330 | 0.190 |
Why?
|
| Databases, Factual | 2 | 2023 | 856 | 0.190 |
Why?
|
| Staphylococcus aureus | 2 | 2021 | 179 | 0.190 |
Why?
|
| Comorbidity | 2 | 2022 | 1119 | 0.190 |
Why?
|
| Pain Management | 2 | 2022 | 169 | 0.190 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2024 | 112 | 0.190 |
Why?
|
| Preoperative Care | 2 | 2020 | 199 | 0.190 |
Why?
|
| Drainage | 1 | 2023 | 155 | 0.180 |
Why?
|
| Tropical Medicine | 1 | 2021 | 1 | 0.180 |
Why?
|
| Nutritional Status | 2 | 2019 | 99 | 0.180 |
Why?
|
| Population Surveillance | 2 | 2021 | 209 | 0.180 |
Why?
|
| Arginine | 4 | 1996 | 131 | 0.180 |
Why?
|
| Occupational Health | 2 | 2020 | 187 | 0.180 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2021 | 27 | 0.180 |
Why?
|
| Global Burden of Disease | 2 | 2019 | 13 | 0.180 |
Why?
|
| Quality Indicators, Health Care | 1 | 2024 | 335 | 0.170 |
Why?
|
| Helminthiasis | 1 | 2021 | 7 | 0.170 |
Why?
|
| Aortic Valve | 1 | 2023 | 190 | 0.170 |
Why?
|
| Caregivers | 1 | 2024 | 283 | 0.170 |
Why?
|
| Streptococcal Infections | 1 | 2021 | 80 | 0.170 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2021 | 42 | 0.170 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2023 | 176 | 0.170 |
Why?
|
| Creatinine | 1 | 2021 | 133 | 0.170 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 89 | 0.170 |
Why?
|
| Patient Safety | 2 | 2020 | 243 | 0.170 |
Why?
|
| Europe | 1 | 2021 | 197 | 0.170 |
Why?
|
| Public Health | 2 | 2019 | 186 | 0.160 |
Why?
|
| China | 1 | 2021 | 170 | 0.160 |
Why?
|
| Anthelmintics | 1 | 2021 | 47 | 0.160 |
Why?
|
| Residence Characteristics | 1 | 2021 | 221 | 0.160 |
Why?
|
| Malnutrition | 1 | 2020 | 41 | 0.160 |
Why?
|
| Research | 1 | 2021 | 196 | 0.160 |
Why?
|
| Skin | 2 | 2020 | 386 | 0.160 |
Why?
|
| Qualitative Research | 1 | 2024 | 729 | 0.160 |
Why?
|
| Aorta, Thoracic | 1 | 2000 | 77 | 0.160 |
Why?
|
| Serum Albumin | 1 | 1999 | 46 | 0.160 |
Why?
|
| Lice Infestations | 1 | 2019 | 1 | 0.160 |
Why?
|
| Tungiasis | 1 | 2019 | 1 | 0.160 |
Why?
|
| Sarcoptes scabiei | 1 | 2019 | 2 | 0.160 |
Why?
|
| Scalp Dermatoses | 1 | 2019 | 4 | 0.160 |
Why?
|
| Travel-Related Illness | 1 | 2019 | 5 | 0.160 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2022 | 219 | 0.150 |
Why?
|
| Organizational Innovation | 1 | 2020 | 82 | 0.150 |
Why?
|
| Myocardial Stunning | 2 | 1996 | 6 | 0.150 |
Why?
|
| Organ Preservation | 2 | 1996 | 21 | 0.150 |
Why?
|
| Medical Staff, Hospital | 1 | 2019 | 59 | 0.150 |
Why?
|
| Myocardium | 3 | 1995 | 287 | 0.150 |
Why?
|
| Mandatory Reporting | 1 | 2018 | 16 | 0.150 |
Why?
|
| Brain Ischemia | 1 | 2023 | 421 | 0.150 |
Why?
|
| Trachoma | 1 | 2018 | 3 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2023 | 511 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 410 | 0.150 |
Why?
|
| Vaccination | 1 | 2021 | 371 | 0.150 |
Why?
|
| Resuscitation | 1 | 2019 | 74 | 0.140 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2018 | 47 | 0.140 |
Why?
|
| Patient Handoff | 1 | 2018 | 35 | 0.140 |
Why?
|
| Cooperative Behavior | 1 | 2020 | 226 | 0.140 |
Why?
|
| Myocardial Ischemia | 2 | 1996 | 117 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 2621 | 0.140 |
Why?
|
| Budgets | 1 | 2017 | 7 | 0.140 |
Why?
|
| Ischemic Attack, Transient | 1 | 1999 | 97 | 0.140 |
Why?
|
| Prognosis | 2 | 2018 | 1769 | 0.140 |
Why?
|
| Multiple Organ Failure | 1 | 2018 | 45 | 0.140 |
Why?
|
| Cost Savings | 1 | 2017 | 55 | 0.130 |
Why?
|
| Fee Schedules | 1 | 2017 | 2 | 0.130 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 150 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2018 | 195 | 0.130 |
Why?
|
| Directive Counseling | 1 | 2017 | 39 | 0.130 |
Why?
|
| Reimbursement, Incentive | 1 | 2017 | 29 | 0.130 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 42 | 0.130 |
Why?
|
| Politics | 1 | 2017 | 37 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2017 | 83 | 0.130 |
Why?
|
| Reminder Systems | 1 | 2017 | 75 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2022 | 708 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 318 | 0.120 |
Why?
|
| Administration, Oral | 3 | 2024 | 374 | 0.120 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 607 | 0.120 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2016 | 43 | 0.120 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 244 | 0.120 |
Why?
|
| Myocardial Reperfusion | 1 | 1995 | 24 | 0.120 |
Why?
|
| Body Mass Index | 1 | 1999 | 874 | 0.120 |
Why?
|
| Urban Population | 1 | 2016 | 198 | 0.120 |
Why?
|
| Reference Values | 1 | 2016 | 333 | 0.120 |
Why?
|
| Mozambique | 2 | 2025 | 2 | 0.120 |
Why?
|
| Communicable Disease Control | 1 | 2015 | 42 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2017 | 205 | 0.120 |
Why?
|
| Adolescent Behavior | 1 | 2017 | 195 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2021 | 711 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 5 | 1996 | 625 | 0.110 |
Why?
|
| Teaching | 1 | 2016 | 164 | 0.110 |
Why?
|
| Interviews as Topic | 1 | 2017 | 540 | 0.110 |
Why?
|
| Program Evaluation | 3 | 2024 | 490 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2019 | 2605 | 0.110 |
Why?
|
| Computer Systems | 1 | 2013 | 14 | 0.100 |
Why?
|
| Computer Graphics | 1 | 2013 | 19 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2024 | 26 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 848 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2018 | 455 | 0.100 |
Why?
|
| Animals | 11 | 2025 | 20956 | 0.100 |
Why?
|
| User-Computer Interface | 1 | 2013 | 126 | 0.100 |
Why?
|
| Injections, Intramuscular | 2 | 2024 | 72 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2017 | 432 | 0.100 |
Why?
|
| Rats | 5 | 1996 | 2006 | 0.100 |
Why?
|
| Lung | 1 | 2018 | 964 | 0.100 |
Why?
|
| Hospital Mortality | 3 | 2025 | 870 | 0.100 |
Why?
|
| Equivalence Trials as Topic | 2 | 2024 | 14 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 163 | 0.100 |
Why?
|
| Comprehension | 1 | 2013 | 139 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2024 | 744 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 192 | 0.090 |
Why?
|
| New Zealand | 2 | 2021 | 43 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2021 | 1375 | 0.080 |
Why?
|
| Kidney | 2 | 2023 | 455 | 0.080 |
Why?
|
| Aorta | 2 | 2022 | 110 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2019 | 67 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2023 | 5528 | 0.060 |
Why?
|
| Pregnancy | 2 | 2024 | 2370 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 1682 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 1996 | 33 | 0.060 |
Why?
|
| Albendazole | 1 | 2025 | 12 | 0.060 |
Why?
|
| Coronary Circulation | 2 | 1996 | 53 | 0.060 |
Why?
|
| Review Literature as Topic | 1 | 2025 | 39 | 0.060 |
Why?
|
| Timor-Leste | 1 | 2024 | 1 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 69 | 0.050 |
Why?
|
| Penicillins | 1 | 2024 | 30 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2024 | 304 | 0.050 |
Why?
|
| Collagenases | 1 | 2023 | 16 | 0.050 |
Why?
|
| Ear | 1 | 2023 | 10 | 0.050 |
Why?
|
| Smoothened Receptor | 1 | 2023 | 27 | 0.050 |
Why?
|
| Anastomosis, Surgical | 1 | 2004 | 117 | 0.050 |
Why?
|
| Epidermis | 1 | 2023 | 37 | 0.050 |
Why?
|
| Alpha-Globulins | 1 | 2023 | 5 | 0.050 |
Why?
|
| Mutant Proteins | 1 | 2023 | 105 | 0.050 |
Why?
|
| Graft Survival | 1 | 2004 | 297 | 0.050 |
Why?
|
| Collagen | 1 | 2023 | 124 | 0.050 |
Why?
|
| Brachiocephalic Trunk | 1 | 2003 | 16 | 0.050 |
Why?
|
| Wound Healing | 1 | 2004 | 192 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2023 | 141 | 0.050 |
Why?
|
| Accidents, Traffic | 2 | 2003 | 147 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2023 | 104 | 0.050 |
Why?
|
| Warfarin | 1 | 2023 | 122 | 0.050 |
Why?
|
| Antioxidants | 1 | 2024 | 256 | 0.050 |
Why?
|
| Elephantiasis, Filarial | 1 | 2022 | 10 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 151 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 20 | 0.050 |
Why?
|
| Geography | 1 | 2021 | 37 | 0.050 |
Why?
|
| Belgium | 1 | 2021 | 6 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2024 | 239 | 0.050 |
Why?
|
| Northern Territory | 1 | 2021 | 6 | 0.040 |
Why?
|
| Netherlands | 1 | 2021 | 25 | 0.040 |
Why?
|
| Education, Nursing, Continuing | 1 | 2021 | 21 | 0.040 |
Why?
|
| Swine | 3 | 2000 | 395 | 0.040 |
Why?
|
| Decontamination | 1 | 2021 | 13 | 0.040 |
Why?
|
| Streptococcus pyogenes | 1 | 2021 | 31 | 0.040 |
Why?
|
| Education, Medical, Continuing | 1 | 2021 | 96 | 0.040 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2000 | 23 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 23 | 0.040 |
Why?
|
| Lipid A | 1 | 2000 | 66 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 233 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 178 | 0.040 |
Why?
|
| Thoracotomy | 1 | 2000 | 47 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 2 | 2000 | 49 | 0.040 |
Why?
|
| Cyclic GMP | 2 | 1996 | 31 | 0.040 |
Why?
|
| Myocardial Contraction | 2 | 1996 | 89 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 869 | 0.040 |
Why?
|
| Pediculus | 1 | 2019 | 1 | 0.040 |
Why?
|
| Phthirus | 1 | 2019 | 1 | 0.040 |
Why?
|
| Tunga | 1 | 2019 | 1 | 0.040 |
Why?
|
| Hematoma | 1 | 2000 | 80 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2019 | 6 | 0.040 |
Why?
|
| Chest Pain | 1 | 2000 | 84 | 0.040 |
Why?
|
| Morbidity | 1 | 1999 | 111 | 0.040 |
Why?
|
| Body Weight | 1 | 2021 | 379 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 48 | 0.040 |
Why?
|
| Lipid Peroxidation | 2 | 1996 | 65 | 0.040 |
Why?
|
| Diet, Carbohydrate Loading | 1 | 2018 | 2 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2018 | 51 | 0.040 |
Why?
|
| Tetracycline | 1 | 2018 | 24 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 299 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 289 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1105 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 109 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 222 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 423 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2019 | 218 | 0.030 |
Why?
|
| Community Health Services | 1 | 2019 | 127 | 0.030 |
Why?
|
| Aging | 1 | 2023 | 754 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2018 | 92 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 587 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 163 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 174 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 467 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 735 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2020 | 315 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 1996 | 63 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 221 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 984 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 577 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 980 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2003 | 1670 | 0.030 |
Why?
|
| Catalase | 1 | 1995 | 23 | 0.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1995 | 29 | 0.030 |
Why?
|
| Electrolytes | 1 | 1995 | 25 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1995 | 92 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 439 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1995 | 175 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1995 | 99 | 0.030 |
Why?
|
| Adenine Nucleotides | 1 | 1995 | 3 | 0.030 |
Why?
|
| Phosphocreatine | 1 | 1995 | 25 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1570 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 1995 | 80 | 0.030 |
Why?
|
| Insulin | 1 | 2018 | 686 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 176 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1995 | 490 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1561 | 0.030 |
Why?
|
| Heart Rate | 1 | 1995 | 328 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 1995 | 271 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 1368 | 0.030 |
Why?
|
| Blood Pressure | 1 | 1995 | 517 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1257 | 0.020 |
Why?
|
| Massachusetts | 1 | 2018 | 2096 | 0.020 |
Why?
|
| Obesity | 1 | 1999 | 1248 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 10994 | 0.020 |
Why?
|
| Inflammation | 1 | 1995 | 1162 | 0.020 |
Why?
|
| Compartment Syndromes | 1 | 2003 | 13 | 0.010 |
Why?
|
| Aortography | 1 | 2003 | 57 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2000 | 44 | 0.010 |
Why?
|
| Guanidines | 1 | 2000 | 13 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2000 | 71 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2003 | 275 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 373 | 0.010 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 1996 | 9 | 0.010 |
Why?
|
| Bilirubin | 1 | 1996 | 18 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 1996 | 21 | 0.010 |
Why?
|
| Temperature | 1 | 1996 | 312 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2000 | 1552 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2000 | 915 | 0.010 |
Why?
|